A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF PF-07081532 ADMINISTRATION ON THE SINGLE-DOSE PHARMACOKINETICS OF DABIGATRAN AND ROSUVASTATIN IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS

The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants. This study also aims to collect data on safety and how tolerable the study medicine is.
The study is seeking for participants who are:
* Male or female who are 18 years of age or older.
* Healthy but are overweight or obese. Participants will receive dabigatran and rosuvastatin as single doses by mouth 3 times during the study. The amount of the study medicine PF-07081532 will be adjusted over time until any interactions are seen.
PF-07081532 is taken daily by mouth in 8 Study Periods while admitted into the study clinic over 53 days. Once discharged from the study clinic, participants will have a follow-up visit 7 to 10 days post last dose of study medicine. Then another follow-up via telephone contact, 28 to 35 days post last dose of study medicine.

开始日期2023-03-27

申办/合作机构

Pfizer Inc.

NCT05745701

/ Completed临床1期

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE-DOSE PHARMACOKINETICS OF PF-07081532 IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS

This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or obese, adult female and male participants.
The 3 study periods will be conducted consecutively without a break.

开始日期2023-02-22

申办/合作机构

Pfizer Inc.

NCT05671653

/ Terminated临床1期

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-07081532 ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, OMEPRAZOLE AND AN ORAL CONTRACEPTIVE, AND THE EFFECT OF STEADY-STATE SEMAGLUTIDE ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, IN OBESE ADULT FEMALE PARTICIPANTS

Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide. The effect of these GLP-1 drugs on a single dose of the common sedative medication midazolam blood levels will be measured. The effect of chronic PF-07081532 on single doses of the common stomach acid medication omeprazole, and common birth control medication blood levels will also be measured. The hypothesis is that chronic administration of the GLP-1 drugs will minimally affect blood levels from these common medications.

开始日期2023-01-19

申办/合作机构

Pfizer Inc.

100 项与 Lotiglipron 相关的临床结果

登录后查看更多信息

100 项与 Lotiglipron 相关的转化医学

登录后查看更多信息

100 项与 Lotiglipron 相关的专利（医药）

登录后查看更多信息

项与 Lotiglipron 相关的文献（医药）

2025-01-01·DIABETES OBESITY & METABOLISM

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

Article

作者: Buckley, Gina ; Vasas, Szilard ; Haggag, Amina Z. ; Frederich, Robert ; Amin, Neeta B. ; Palmer, Alexandra ; Zhu, Qi ; DuBrava, Sarah J. ; Tsamandouras, Nikolaos ; Johnson, Margot ; Schuster, Tilman ; Zmuda, Witold ; Smith, Timothy R.

Abstract:

Aim:

The aim was to investigate the effects of lotiglipron, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in participants with type 2 diabetes (T2D) or obesity.

Materials and Methods:

A phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study investigated the efficacy and safety of lotiglipron. The study was terminated early for safety reasons after routine data and monitoring review. The planned analyses for the end points were modified prior to unblinding the study.

Results:

In total, 901 participants were treated with at least one dose of the study drug (T2D cohort: n = 512, obesity cohort: n = 389). Although the majority of participants who were randomly assigned to higher doses did not reach their target maintenance dose, statistically significant changes in HbA1c and body weight were observed. In the T2D cohort, reductions in HbA1c were observed across all lotiglipron doses at week 16 (p < 0.0001), with least squares mean decreases up to −1.44% (90% confidence interval [CI]: −1.63, −1.26) (lotiglipron 80 mg), versus placebo, −0.07% (90% CI: −0.25, 0.11). In the obesity cohort, decreases in body weight were observed across all lotiglipron doses at week 20 (p < 0.01), up to −7.47% (90% CI: −8.50, −6.43) (lotiglipron 200 mg, five‐step titration), versus placebo, −1.84% (90% CI: −2.85, −0.83). Across cohorts, the most frequently reported treatment‐emergent adverse events were gastrointestinal related (most mild to moderate severity), with nausea being the most common (ranging from 4% [placebo] to 28.8% [80 mg] in the T2D cohort and 12.5% [placebo] to 60.6% [200 mg, four‐step titration] in the obesity cohort). Transaminase elevations were observed in a subset of participants (6.6% and 6.0% of participants on lotiglipron in the T2D and obesity cohorts, respectively, compared with 1.6% on placebo in the obesity cohort).

Conclusions:

The efficacy (HbA1c and/or body weight) of a range of lotiglipron doses was demonstrated in T2D and obesity cohorts. The safety profile was largely consistent with what has been previously known about the mechanism of action. Our results are unique in reporting elevations in liver transaminases in a subset of participants treated with lotiglipron, with attempts to identify the at‐risk population unsuccessful and therefore clinical development of lotiglipron terminated.

ClinicalTrials.gov:

NCT05579977.

2024-12-18·Science Translational Medicine

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

Article

作者: Willard, Francis S. ; Suter, Todd M. ; Emmerson, Paul J. ; Padgett, Leah R. ; Hewitt, Natalie ; White, Alex ; O’Farrell, Libbey S. ; Peterson, Jeffrey A. ; Sangwung, Panjamaporn ; Liu, Zhaomin ; Wainscott, David B. ; Coskun, Tamer ; Ruble, J. Craig ; Cox, Amy L. ; Sloop, Kyle W. ; Showalter, Aaron D. ; Snider, Brandy M. ; Dunbar, James D. ; Stutsman, Cynthia ; Coutant, David E. ; Woerly, Eric M. ; Ai, Minrong ; Droz, Brian A.

Orally bioavailable, synthetic nonpeptide agonists (NPAs) of the glucagon-like peptide-1 receptor (GLP-1R) may offer an effective, scalable pharmacotherapy to address the metabolic disease epidemic. One of the first molecules in the emerging class of GLP-1R NPAs is orforglipron, which is in clinical development for treating type 2 diabetes and obesity. Here, we characterized the pharmacological properties of orforglipron in comparison with peptide-based GLP-1R agonists and other NPAs. Competition binding experiments using either [ 125 I]GLP-1(7-36)NH 2 or [ 3 H]orforglipron indicated that orforglipron is a high-affinity [inhibition constant ( Ki ) = 1 nM], selective ligand of the human GLP-1R. Signal transduction assays showed that orforglipron has low intrinsic efficacy for effector activation and negligible β-arrestin recruitment. To evaluate GLP-1R engagement in vivo, mice expressing the human GLP-1R were administered orforglipron and subjected to a glucose tolerance test. Predicted receptor occupancy was calculated using the receptor Ki value of orforglipron and its unbound concentration in vivo that reduces hyperglycemia. These experiments revealed that low GLP-1R occupancy by orforglipron is sufficient to yield a full biological response. Moreover, in a model where CRISPR-Cas9 gene editing was used to sensitize the rat GLP-1R ( Glp1r S33W ) to GLP-1R NPAs, target engagement by orforglipron in the pancreas and brain was consistent with peptide-based GLP-1R agonists. Diet-induced obesity in Glp1r S33W rats enabled studies showing weight loss in animals orally administered orforglipron versus subcutaneous injection of GLP-1R agonist semaglutide. Furthermore, crossover studies indicated oral orforglipron can sustain efficacy initiated by parenteral semaglutide. The pharmacological properties of orforglipron may inform targeting of other peptide receptors with NPAs.

2024-08-01·DIABETES OBESITY & METABOLISM

Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies

Article

作者: Tsamandouras, Nikolaos ; Brown, Lisa S. ; Saxena, Aditi R. ; Carvajal‐Gonzalez, Santos ; Buckeridge, Clare ; Hernandez‐Illas, Martha

Abstract:

Aim:

To investigate the effects of lotiglipron (PF‐07081532), a once‐daily, oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in participants with type 2 diabetes (T2D) and/or obesity.

Materials and Methods:

Two Phase 1 randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies were conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of lotiglipron.

Results:

Across the studies, 74 participants with T2D were treated for 28 or 42 days, and 26 participants with obesity without diabetes were treated for 42 days, following randomization to placebo or lotiglipron (target doses 10–180 mg/day, with dose titration to higher target doses). Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. There were no clinically meaningful adverse trends noted in safety laboratory tests, vital signs, or electrocardiogram parameters. In participants with T2D, lotiglipron resulted in dose‐dependent reductions in mean daily glucose. The 180‐mg dose was associated with least squares mean decreases from baseline in glycated haemoglobin (−1.61% [90% confidence interval {CI} –2.08, −1.14] vs. −0.61% [−1.56, 0.34] for placebo) and body weight (−5.10 kg [90% CI –6.62, −3.58] vs. −2.06 kg [90% CI –4.47, 0.36] for placebo) after 42 days; a similar magnitude of weight loss was seen in participants with obesity. The observed pharmacokinetic profile supported once‐daily dosing.

Conclusions:

The profile of once‐daily lotiglipron with doses up to 180 mg, as observed in these two Phase 1 studies, indicated a safety and tolerability profile consistent with the mechanism of action, with dose‐dependent reductions in glycaemic indices (T2D) and body weight (both populations) after multiple doses. Clinicaltrials.gov identifier: NCT04305587, NCT05158244.

101

项与 Lotiglipron 相关的新闻（医药）

2025-07-07

·医药投资部落

AI设计的国产小分子GLP-1，给礼来上了压力

现有GLP-1药物（如司美格鲁肽、利拉鲁肽）多为注射剂型，尽管成功的长效化剂型开发，已实现每周一次甚至每月一次的注射频率，但全球真实世界研究显示：因恐针、疼痛或操作不便等各种原因，仅约50%患者能坚持注射治疗1年以上，2年持续使用率降至约30%。鉴于上述原因，对于口服剂型的小分子GLP-1药物的开发，是近年来全球医药行业竞逐的一个热点方向。2025年6月19日，杭州，一家专注于使用人工智能驱动新药研发的公司「德睿智药」宣布，其自主研发的口服小分子GLP-1RA新药MDR-001片，在治疗肥胖或超重适应症的多中心24周IIb期临床试验中，成功达到临床终点。研究结果表明，肥胖或超重受试者在接受MDR-001片治疗24周时，给药组减重高达10.3%，安慰剂组减重为2.5%（P<0.00001），经安慰剂调整后的平均减重范围为-7.1%至-7.8%，且安全性、耐受性优异。口服MDR-001片各剂量组体重较基线降低-8.2%至-10.3%，绝对减重7.4至9.2kg，而安慰剂组仅为2.4kg（P<0.00001）；高达70.9%至85.4%的受试者减重≥5%，34.5%至48.1%受试者减重≥10%。同时，MDR-001在改善多个代谢和心血管疾病相关参数方面表现出色，包括腰围、血脂、血压等指标，有望为患者带来全面的临床获益。就在此前不久的2025年4月，全球医药巨头礼来，也宣布其小分子GLP-1受体激动剂Orforglipron治疗二型糖尿病三期临床试验获得成功。作为这项临床试验的关键次要终点，orforglipron最高剂量组的入组患者，在第40周时，实现平均体重减轻7.3kg（7.9%）。从入组患者的基线体重而言，礼来的这个三期临床试验，入组患者基准体重为90.2公斤，而德睿智药的二期临床试验，入组患者基准体重为90.1公斤，二者极为接近，因此具备非头对头比较的意义。德睿智药的MDR-001片治疗24周时，患者的减重比例就达到了10.3%，超过了礼来orforglipron治疗40周时的7.9%。在2023年，礼来曾经公布过orforglipron的二期临床试验数据，其最高剂量组的减重幅度达到了12.6%，但是该二期临床试验的入组患者的基准体重，达到了108.7公斤，显著超过了德睿智药此次二期临床试验的入组患者90.1公斤的基准体重。除了减重效果之外，优异的安全性是德睿智药MDR-001片所体现的另一个显著优势。事实上，在小分子GLP-1领域，安全性可能是比减重效果更让大家关注的一个核心指标。由于安全性而导致的小分子GLP-1药物研发失败，曾经让不少跨国药企损失惨重。最突出的案例，就是辉瑞公司两款小分子GLP-1受体激动剂的研发失败。2023年6月，因转氨酶升高问题，辉瑞医药的Lotiglipron被终止研发。2023年12月，辉瑞医药的另一款小分子GLP-1药物Danuglipron，其每日两次服用的制剂，因耐受性问题被终止研发。数据显示，这款药物的临床试验中，高达73%的患者出现恶心，47%出现呕吐，25%出现腹泻，停药率超过50%。在2025年4月，Danuglipron每日一次的缓释制剂，因潜在肝损伤风险，也被终止研发。原因是有一名无症状参与者出现了潜在的药物诱导性肝损伤。相比之下，德睿智药MDR-001片，目前读出的安全性数据，堪称优异。试验期间，MDR-001片没有出现药物治疗相关严重不良事件（SAE）。各治疗组主要不良事件为胃肠道反应，包括恶心、呕吐和腹泻，多为轻中度且集中发生在滴定期前6周内, 中位恢复时间约为1-5天。同时，受试者整体肝脏方面安全性表现良好，值得注意的是，本研究给药组纳入了约20%既往病史肝功能异常和转氨酶升高的受试者，各组未观察到转氨酶升高的趋势，且相比安慰剂组，MDR-001治疗组的转氨酶较基线均有明显降低。整个MDR-001片的二期临床试验，仅有2例（0.8%）因治疗期间出现的不良事件（TEAE）终止治疗。相比之下，礼来的Danuglipron，其最新公布的临床试验数据，由于不良事件导致的总体治疗中断率分别为：3mg组6%，12mg组4%，36mg组8%。目前，MDR-001片需要每日服用2次，相比于Danuglipron每日服用一次，这是一个小小的劣势。据悉，德睿智药正在积极推进MDR-001片3期临床试验的准备，并在探索每日一次的给药方案中取得积极进展。医药研究报告分享营收集与分享全市场主流医药研究报告每天仅需0.8元畅享超过2000篇存量精选医药研究报告每年新增额外500篇

临床2期临床3期临床成功临床结果

2025-06-28

·同写意

别再为GLP-1里的炒作“买单”

上市批准

2025-06-24

·药事纵横

礼来口服GLP-1 orforglipron III期报捷，突破肝毒性困局！

6月21日，在美国糖尿病协会（ADA）第85届科学会议上，礼来公司公布了其口服GLP1受体激动剂orforglipron的III期ACHIEVE1研究详细数据。结果显示，该药物在显著降低血糖和体重的同时，未出现辉瑞同类药物遭遇的肝毒性问题，安全性特征与现有注射型GLP1疗法一致。早先，肝毒性这一障碍曾直接导致辉瑞同类药物danuglipron于今年4月终止研发。疗效数据亮眼ACHIEVE-1研究结果揭示，orforglipron在559例2型糖尿病患者中展现出显著的降糖疗效。基线HbA1c为8.0%的患者，经40周治疗后，3mg、12mg、36mg剂量组分别实现1.3%、1.5%、1.6%的降幅，而安慰剂组仅下降0.1%。值得关注的是，最高剂量组有76.2%的患者达到ADA制定的HbA1c<7%控制目标，25.8%的患者甚至实现HbA1c<5.7%的糖化正常值。这种早期起效特性尤为突出，治疗仅4周即观察到血糖改善，较传统口服降糖药具有明显优势。在减重方面，36mg剂量组患者体重平均下降7.3kg（7.9%），这一数据虽略低于诺和诺德注射用司美格鲁肽在STEP系列研究中观察到的15%体重降幅，但已超越多数口服减肥药的疗效阈值。体重下降曲线在40周时仍未显现平台期，暗示延长治疗周期可能带来更显著获益。这种持续减重效应与药物作用机制密切相关，GLP-1受体激动剂通过延缓胃排空、抑制食欲中枢、调节能量代谢等多途径发挥减重作用，其效果往往随治疗时间延长而增强。安全性方面，orforglipron延续了GLP-1类药物典型的胃肠道反应特征。试验中19%-26%患者发生腹泻，13%-18%出现恶心，11%-20%报告消化不良，但绝大多数为轻中度且发生于剂量递增期。通过阶梯式给药方案，即前4周从低剂量起始并逐步加量，研究团队将因不良反应导致的停药率控制在4.4%-7.8%区间，显著低于辉瑞danuglipron早期试验中超50%的脱落率。这种剂量优化策略的成功实践，为口服多肽类药物的研发提供了重要范式。绕过辉瑞折戟的“肝毒性陷阱”今年4月，辉瑞公司的danuglipron因受试者出现肝酶升高伴胆红素异常，这款处于II期临床的口服药物被紧急叫停。尽管停药后肝功能指标恢复，但FDA要求补充的长期肝毒性研究，使得项目进度严重滞后。这并不是辉瑞首次在口服GLP1领域遭遇挫折，2023年6月，辉瑞因肝酶升高问题终止了另一款口服GLP1候选药物lotiglipron的研发，此后，辉瑞又因患者耐受性问题放弃了每日两次给药的danuglipron版本，仅保留每日一次剂型继续开发。相较之下，orforglipron在ACHIEVE-1研究中的安全性表现更为突出，各剂量组肝酶升高发生率与安慰剂组无统计学差异，且所有异常指标均在用药期间自行缓解，未出现药物性肝损伤病例。这种安全性差异可能源于分子结构的本质区别。作为非肽类小分子药物，orforglipron无需通过肝脏首过效应代谢，避免了多肽类药物常见的肝细胞色素P450酶系代谢负担，其化学结构中的环己基甲基酰胺基团，被证实可增强肠道吸收同时减少肝肠循环，这种独特的药代动力学特性或许是其肝脏安全性优势的分子基础。此外，礼来在剂量爬坡阶段采用的"4周滴定法"，较传统2周滴定方案更能实现血药浓度的平稳过渡，有效降低急性药物暴露引发的应激反应。口服剂型的革新意义GLP1类药物虽已成为糖尿病和肥胖治疗的热点，但其应用仍受限于成本、医保覆盖以及注射给药方式。研究表明，相当一部分糖尿病患者对注射存在心理障碍，导致治疗延迟或完全回避。目前唯一上市的口服GLP1药物是诺和诺德的Rybelsus（口服司美格鲁肽），但其使用有严格限制：必须在空腹状态下服用，服药前后30分钟内不能进食或饮水（少量水除外），以防止药物在胃内降解。相比之下，orforglipron作为非肽类小分子药物，不受食物和饮水影响，可在一天中任意时间服用，大大提高了用药便利性和患者依从性。这种使用便捷性可能改变糖尿病和肥胖症的治疗模式，使更多患者能够接受并坚持GLP1疗法。口服GLP1药物市场正经历激烈角逐，礼来orforglipron的成功，为该公司在这一巨大市场中赢得了有利位置。礼来计划在2025年底前提交orforglipron用于体重管理的上市申请，2026年提交其用于治疗2型糖尿病的申请。如果计划按时进行，那么礼来将成为口服GLP1领域的先行者之一。目前，礼来正在进行orforglipron的七项III期研究，涉及超过6，000名2型糖尿病和肥胖患者。今年第三季度，预计将公布ATTAIN1和ATTAIN2研究的结果，这两项研究评估orforglipron用于体重管理的效果。礼来还将在年底前公布两项关键研究的顶线结果：ACHIEVE2研究比较orforglipron与阿斯利康SGLT2抑制剂达格列净（dapagliflozin）的疗效；ACHIEVE3研究则直接对比orforglipron与诺和诺德的口服司美格鲁肽。这些头对头研究结果将进一步明确orforglipron在同类药物中的地位。尽管数据亮眼，orforglipron仍需直面两大挑战：其一是与已上市口服减肥药的头对头比较。即将公布的ACHIEVE-3研究（对比口服司美格鲁肽）将成为关键试金石，若能在减重幅度或治疗满意度上实现非劣效性，将极大增强其市场说服力。其二是长期安全性验证，特别是心血管结局和胰腺安全性。FDA已要求补充为期5年的心血管预后研究，这要求礼来在2028年前完成超过12000例患者的入组。礼来当前的重大突破与之前辉瑞因安全性折戟共同展现了生物医药创新的高风险与高回报特点，安全性始终是药物研发不可逾越的底线，也是患者获得有效治疗的基本保障。信息来源：[1]Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Jun 21. DOI: 10.1056/NEJMoa2505669.[2]Lilly.Phase 3 ACHIEVE-1 Trial Results: Orforglipron in Type 2 Diabetes. Presented at the American Diabetes Association (ADA) 85th Scientific Sessions; 2025 Jun 21; Philadelphia, USA.药事纵横投稿须知：稿费已上调，欢迎投稿

临床3期临床结果临床成功临床失败

100 项与 Lotiglipron 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床2期	美国	Pfizer Inc.	2022-10-27
2型糖尿病	临床2期	日本	Pfizer Inc.	2022-10-27
2型糖尿病	临床2期	保加利亚	Pfizer Inc.	2022-10-27
2型糖尿病	临床2期	加拿大	Pfizer Inc.	2022-10-27
2型糖尿病	临床2期	捷克	Pfizer Inc.	2022-10-27
2型糖尿病	临床2期	匈牙利	Pfizer Inc.	2022-10-27
2型糖尿病	临床2期	波兰	Pfizer Inc.	2022-10-27
2型糖尿病	临床2期	波多黎各	Pfizer Inc.	2022-10-27
肥胖	临床2期	美国	Pfizer Inc.	2022-10-27
肥胖	临床2期	日本	Pfizer Inc.	2022-10-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05788328 (CTgov)	临床1期	肥胖	16	DE (Period 1: DE 150 mg)	築醖醖廠鹹顧糧餘夢簾(鹹蓋夢糧觸鏇鑰築願築) = 糧繭醖壓廠膚齋製衊築範夢簾網製築齋齋鑰壓 (襯憲夢廠繭淵鹽艱醖鹽, 43) 更多	-	2024-11-15
				DE+PF-07081532 (Period 4: DE 150 mg + PF-07081532 80 mg QD)	築醖醖廠鹹顧糧餘夢簾(鹹蓋夢糧觸鏇鑰築願築) = 積選築繭蓋願鑰選夢構範夢簾網製築齋齋鑰壓 (襯憲夢廠繭淵鹽艱醖鹽, 38) 更多
NCT05510245 (CTgov)	临床1期	2型糖尿病 \| 功能障碍	18	PF-07081532 (Mild Renal Impairment)	築鑰鏇製積構廠醖衊蓋(夢顧膚鏇範觸構築壓鹽) = 構蓋築窪衊鹹衊夢鬱構遞廠餘襯鹹鹽顧鏇夢餘 (鹽鑰膚窪遞鑰製廠鏇範, 50) 更多	-	2024-11-05
				PF-07081532 (Moderate Renal Impairment)	築鑰鏇製積構廠醖衊蓋(夢顧膚鏇範觸構築壓鹽) = 窪鹹鬱積鹽鏇廠構醖餘遞廠餘襯鹹鹽顧鏇夢餘 (鹽鑰膚窪遞鑰製廠鏇範, 24) 更多
NCT05652647 (CTgov)	临床1期	-	6	[14C]PF-07081532 (Period 1: [14C]PF-07081532 30 mg Oral)	築夢鹹鹹襯夢糧構襯網(糧鬱繭遞選網膚餘鏇獵) = 繭鏇網遞鑰築壓蓋簾糧壓壓簾選醖壓艱網構築 (襯遞繭鬱衊鑰襯襯鬱齋, 0.6) 更多	-	2024-09-24
				[14C]PF-07081532 (Period 2: PF-07081532 30 mg Oral + [14C]PF-07081532 100 µg IV)	餘選齋鏇鬱壓窪壓壓鑰(衊襯襯製餘遞壓齋繭醖) = 築夢夢壓範鏇鹽築鏇醖製積選遞網觸齋糧窪淵 (鬱廠遞膚衊艱淵蓋窪積, 32) 更多
NCT05745701 (CTgov)	临床1期	肥胖	16	Lotiglipron (Active Comparator: Period 1: Lotiglipron)	鹽積遞鏇構顧遞構鹽願(觸構淵蓋鏇襯襯鹽蓋鹽) = 鏇獵鹽鹽醖窪憲鹹製糧艱夢獵遞製製願網願觸 (淵艱鏇遞壓鬱繭構襯憲, 49) 更多	-	2024-09-23
				Cyclosporine+Lotiglipron (Experimental: Period 2: Lotiglipron + Cyclosporine)	鹽積遞鏇構顧遞構鹽願(觸構淵蓋鏇襯襯鹽蓋鹽) = 襯餘鏇夢襯遞製齋製醖艱夢獵遞製製願網願觸 (淵艱鏇遞壓鬱繭構襯憲, 62) 更多
NCT05478603 (CTgov)	临床1期	肝损伤	24	PF-07081532 (Without Hepatic Impairment)	壓構鑰遞構簾憲製鹹艱(齋窪糧衊製淵築鹽淵廠) = 鬱網憲廠簾醖膚壓憲製膚網廠觸鹽壓醖簾鑰憲 (夢觸選齋獵夢網繭遞願, 10) 更多	-	2024-08-22
				PF-07081532 (Mild Hepatic Impairment)	壓構鑰遞構簾憲製鹹艱(齋窪糧衊製淵築鹽淵廠) = 網網網襯廠艱憲顧襯遞膚網廠觸鹽壓醖簾鑰憲 (夢觸選齋獵夢網繭遞願, 18) 更多
NCT05158244 (CTgov)	临床1期	2型糖尿病	34	Placebo (Placebo (Type 2 Diabetes Mellitus [T2DM]))	鹽廠蓋鏇積鬱廠製構顧 = 製觸窪襯築築製蓋製範製鏇觸簾壓衊鬱積繭鹽 (顧淵廠窪鬱窪醖範衊築, 衊憲構繭鏇醖餘廠願鏇 ~ 齋襯餘醖簾製積製鹹壓) 更多	-	2024-08-12
				PF-07081532 (PF-07081532 20-60 mg (T2DM))	鹽廠蓋鏇積鬱廠製構顧 = 糧選選築餘網製網顧衊製鏇觸簾壓衊鬱積繭鹽 (顧淵廠窪鬱窪醖範衊築, 淵範窪蓋鹹製顧夢齋觸 ~ 製選齋餘膚鹹衊簾餘鹽) 更多
NCT05158244 \| NCT04305587 (Pubmed) 人工标引	临床1期	2型糖尿病 \| 肥胖	74	Lotiglipron 10mg/day	鏇選顧淵積窪憲鬱廠醖(窪窪醖鹽鹽糧網鑰壓餘) = Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. 積窪簾顧廠壓觸醖蓋獵 (鬱繭製憲醖蓋築鑰繭網 )	积极	2024-08-01
				lotiglipron 180-mg (T2D)
NCT04305587 (Phase 1, CTgov)	临床1期	2型糖尿病	66	Placebo (Placebo Part A)	觸窪廠獵鹽繭壓鏇膚餘 = 網夢憲夢鬱遞鹽膚網築鏇齋衊網構築繭淵憲積 (齋顧襯顧餘廠製憲願築, 壓觸鏇鬱選積築糧夢蓋 ~ 廠獵鏇鹽壓網範窪鬱鏇) 更多	-	2024-02-05
				PF-07081532 (PF-07081532 10 mg Part A)	觸窪廠獵鹽繭壓鏇膚餘 = 積糧鹹獵製齋簾積蓋衊鏇齋衊網構築繭淵憲積 (齋顧襯顧餘廠製憲願築, 膚膚製鏇獵鹽壓願艱鏇 ~ 廠築繭繭構網醖顧製願) 更多
NCT04305587 (Phase 1, EASD2022)	临床1期	2型糖尿病 \| 肥胖	-	PF-07081532	襯鹽遞選廠壓艱憲選衊(壓鬱觸餘選鬱窪鬱顧憲) = Most adverse events were mild and consistent with the mechanism of action. No clinically significant, adverse trends in laboratory measures, electrocardiogram or vital sign abnormalities were apparent. 鬱範鑰願範獵鏇範獵鏇 (廠鹽廠醖顧醖網衊窪繭 )	积极	2022-09-21
NCT05158244 (Corporate Publications) 人工标引	临床1期	2型糖尿病	34	PF 07081532	醖製簾襯獵積鏇鹹鬱網(鬱積餘簾鏇築窪觸窪齋) = 糧醖鬱願築衊夢壓襯繭夢醖壓築鹽齋選鏇製餘 (獵選獵夢鹽築構顧壓觸 ) 更多	积极	2022-08-10
				Placebo	醖製簾襯獵積鏇鹹鬱網(鬱積餘簾鏇築窪觸窪齋) = 夢憲鑰選鹽鹹製鬱膚積夢醖壓築鹽齋選鏇製餘 (獵選獵夢鹽築構顧壓觸 ) 更多